Previous 10 | Next 10 |
REDWOOD CITY, Calif., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today announced the initiation of sunRIZE, a pivotal Phase 3...
REDWOOD CITY, Calif., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today announced the completion of enrollment in its RZ402 Ph...
Dallas, Texas--(Newsfile Corp. - November 24, 2023) - Stonegate Healthcare Partners highlights a unique opportunity in its report, "Black Friday Biotech Sale: 12 Stocks for XBI-MAS." Despite overall market health, biotech stocks have significantly declined, with the XBI biotech index 56% lower th...
REDWOOD CITY, Calif., Nov. 17, 2023 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today announced that the management team will participate in...
2023-11-14 02:19:35 ET More on Rezolute Rezolute: Negative EV Opportunity Initiating A Phase 3 Ultra-Orphan Pediatric Study Seeking Alpha’s Quant Rating on Rezolute Historical earnings data for Rezolute Financial information for Rezolute For fu...
REDWOOD CITY, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today announced its financial results for the first quarter ...
2023-11-09 18:57:06 ET Summary Rezolute is a clinical-stage biotechnology company focused on metabolic diseases related to glucose control. Their lead asset, RZ358, is a monoclonal antibody being developed as a treatment for hyperinsulinism, a condition characterized by excessive ...
Evotec SE (EVO) is expected to report $-0.03 for Q3 2023 Amplifon (AMFPF) is expected to report for Q3 2023 Compass Therapeutics Inc. (CMPX) is expected to report $-0.11 for Q3 2023 Astronics Corp. - Class B (ATROB) is expected to report for Q4 2023 Charge Enterprises Inc. (CRGE) ...
Rezolute Inc. (RZLT) is expected to report $-0.33 for Q1 2024
REDWOOD CITY, Calif., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today announced that the European Medicines Agency (EMA) has...
News, Short Squeeze, Breakout and More Instantly...
REDWOOD CITY, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, t...
Shares of Rezolute, Inc. (NASDAQ: RZLT) traded at a new 52-week high today and are currently trading at $2.99. So far today, approximately 207.71k shares have been exchanged, as compared to an average 30-day volume of 238.24k shares. Rezolute, Inc., a clinical stage biopharmaceutical company,...
The Dow Jones index closed higher by around 0.1% on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern aroun...